The National Cancer Institute (NCI) is offering a grant to support exploratory research projects aimed at developing and validating emerging technologies to enhance the quality of biospecimens used in cancer research and clinical care. This grant focuses on overcoming feasibility gaps in technology with preliminary data, requiring further development and validation. The goal is to improve sample integrity using innovative tools, devices, and methods to minimize pre-analytical variations. Ultimately, this funding opportunity seeks to advance cancer biology, early detection, clinical diagnosis, and treatment by addressing biospecimen quality issues. Deadline for applications is September 28, 2018.
Opportunity ID: 298896
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | RFA-CA-18-005 |
Funding Opportunity Title: | Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 – Clinical Trial Not Allowed) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Education Health |
Category Explanation: | – |
Expected Number of Awards: | 2 |
Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Nov 20, 2017 |
Last Updated Date: | – |
Original Closing Date for Applications: | Sep 28, 2018 |
Current Closing Date for Applications: | Sep 28, 2018 |
Archive Date: | Nov 03, 2018 |
Estimated Total Program Funding: | $900,000 |
Award Ceiling: | $300,000 |
Award Floor: | – |
Eligibility
Eligible Applicants: | For profit organizations other than small businesses Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Small businesses Independent school districts Private institutions of higher education Special district governments Native American tribal organizations (other than Federally recognized tribal governments) County governments |
Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
Agency Name: | National Institutes of Health |
Description: | This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. |
Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-18-005.html |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Related Documents
There are no related documents on this grant.
Packages
Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
FORMS-E | Use for due dates on or after January 25, 2018 | PKG00236441 | Jan 28, 2018 | Sep 28, 2018 | View |
Package 1
Mandatory forms
298896 RR_SF424_2_0-2.0.pdf
298896 PHS398_CoverPageSupplement_4_0-4.0.pdf
298896 RR_OtherProjectInfo_1_4-1.4.pdf
298896 PerformanceSite_2_0-2.0.pdf
298896 RR_KeyPersonExpanded_2_0-2.0.pdf
298896 RR_Budget_1_4-1.4.pdf
298896 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
298896 RR_SubawardBudget30_1_4-1.4.pdf
298896 PHS_AssignmentRequestForm_2_0-2.0.pdf